跳至主要内容
临床试验/NL-OMON43219
NL-OMON43219招募中不适用

18F-FDHT PET/CT for re-staging patients with recurrent of prostate cancer after radiotherapy; a pilot study - FDHT PET/CT for restaging recurrent prostate cancer

niversitair Medisch Centrum Groningen0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Histologically proven prostate cancer for which the subject has undergone radiotherapy with curative intent
  • - Biochemical recurrence according to Phoenix criteria (PSA nadir +2 ng/mL)
  • - PSA <10 ng/mL
  • - Written informed consent
  • - No androgen deprivation therapy in the past 12 months
  • - Planned for restaging or patients who have recently have been restaged with a mpMRI and 68 Ga-PSMA PET/CT (last scan not more than 28 days ago)

排除标准

  • - Active cancer besides prostate cancer
  • - Suspected metastases
  • - PSA > 10 ng/mL
  • - Androgen deprivation therapy in the past 12 months
  • - A contra-indication for undergoing MRI. (namely implants containing metal or metal schrapnels in the eyes or body and claustrophobia)

研究者

相似试验